Skip to content

TREC@TAMU Cancer Prevention Registry and Repository

Texas Regional Excellence in Cancer (TREC) @Texas A&M University Cancer Prevention Registry and Repository

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06826014
Enrollment
2500
Registered
2025-02-13
Start date
2025-03-31
Completion date
2030-11-30
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Diet, Disease, Genetics, Lifestyle Factors

Keywords

cancer, genetics

Brief summary

This study collects health and genetic information to implement cancer prevention and treatment strategies.

Detailed description

This research will explore how genetics, diet, exercise, and jobs influence the risk of developing cancers that can be treated early. The goal is to find out if this knowledge can help doctors and health insurers improve their methods for preventing cancers that cannot be treated.

Interventions

None listed

Sponsors

Texas A&M University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age and older, and, * People participating in the Cancer Prevention and Research Institute of Texas (CPRIT) A coordinated cancer screening research program in Bryan and Navasota Family Medicine Clinics and, * People with COPD, liver disease, cervical intraepithelial neoplasia (CIN) lesions, having had a colonoscopy or a low dose computed tomography (LDCT) lung scan or cervical exam in the last 12 months or scheduled for one, and, * Able to give and comprehend the consent process, and, * Able to consent to donate blood and urine samples, genetic material through buccal swabs for future research, and, * Able to understand that their specimens, health record, and changes in health status will be followed for a five-year period and shared in deidentified form with the research community, and, * All sexes and gender identities.

Exclusion criteria

* Declines to participate or interact with staff/share their medical status. * A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning Individuals who are unable or unwilling to provide consent will be excluded

Design outcomes

Primary

MeasureTime frameDescription
Frequency and nature of ADRs on the Naranjo Scale Questionnaire5 yearsMeasure the frequency and nature of adverse drug reactions by obtaining a complete medical history and physical examination and validating the patient's current concomitant medication list during the office visit. Patient medical information would be input into the ActX platform, which functions as a computable EHR medical record analysis, evaluation of polypharmacy status, and monitoring of ADRs using the Naranjo Scale will be conducted for the duration of the study.

Secondary

MeasureTime frameDescription
Self-reported Health status and any significant changes5 yearsThe EQ-5D-5L survey, designed to collect data on health status and significant changes, will be administered to every patient in the registry at each clinic visit and at least every six months for five years after enrollment. The EQ-5D-5L consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension features five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Patients indicate their health state by ticking the box next to the most appropriate statement for each dimension. This choice generates a one-digit number representing the selected level for that dimension. The numbers from the five dimensions can be combined into a five-digit number that characterizes the patient's health state.

Countries

United States

Contacts

Primary ContactKenneth S Ramos, MD
kramos@tamu.edu7136777740
Backup ContactRick Silva, PhD
ricksilva@tamu.edu(713) 677-7422

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026